Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emilio Portaccio

Showing results (1-10 of 151) with videos related to

Pageof 16
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 2, 2024
Toward a holistic approach to multiple sclerosis: The role of social determinants of healthEmilio Portaccio
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 17, 2018
A decline in cognitive function should lead to a change in disease-modifying therapy - NoEmilio Portaccio
Core Evidence|April 7, 2011
Evidence-based assessment of potential use of fingolimod in treatment of relapsing multiple sclerosisEmilio Portaccio
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 11, 2024
Maternal smoking and multiple sclerosis risk in offspring: A further clue of prenatal environmental triggersEmilio Portaccio, Pietro Iaffaldano
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 28, 2024
Progression independent of relapse activity in multiple sclerosis: Time to account for cognitive declineCarmen Tur, Emilio Portaccio
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 1, 2022
Reliable change indices for cognitive assessment of patients with multiple sclerosisEmilio Portaccio, Maria Pia Amato
Expert Review of Neurotherapeutics|August 26, 2011
Is there a future for donepezil therapy in the treatment of multiple sclerosis-related cognitive impairment?Maria Pia Amato, Emilio Portaccio
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 8, 2011
Truly benign multiple sclerosis is rare: let's stop fooling ourselves--yesMaria Pia Amato, Emilio Portaccio
CNS Drugs|March 17, 2015
Fertility, pregnancy and childbirth in patients with multiple sclerosis: impact of disease-modifying drugsMaria Pia Amato, Emilio Portaccio
CNS Drugs|June 2, 2009
Improving compliance with interferon-beta therapy in patients with multiple sclerosisEmilio Portaccio, Maria Pia Amato
Pageof 16

Showing results (1-10 of 151) with videos related to

Sort By:
Pageof 16
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 2, 2024
Toward a holistic approach to multiple sclerosis: The role of social determinants of healthEmilio Portaccio
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 17, 2018
A decline in cognitive function should lead to a change in disease-modifying therapy - NoEmilio Portaccio
Core Evidence|April 7, 2011
Evidence-based assessment of potential use of fingolimod in treatment of relapsing multiple sclerosisEmilio Portaccio
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 11, 2024
Maternal smoking and multiple sclerosis risk in offspring: A further clue of prenatal environmental triggersEmilio Portaccio, Pietro Iaffaldano
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 28, 2024
Progression independent of relapse activity in multiple sclerosis: Time to account for cognitive declineCarmen Tur, Emilio Portaccio
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 1, 2022
Reliable change indices for cognitive assessment of patients with multiple sclerosisEmilio Portaccio, Maria Pia Amato
Expert Review of Neurotherapeutics|August 26, 2011
Is there a future for donepezil therapy in the treatment of multiple sclerosis-related cognitive impairment?Maria Pia Amato, Emilio Portaccio
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 8, 2011
Truly benign multiple sclerosis is rare: let's stop fooling ourselves--yesMaria Pia Amato, Emilio Portaccio
CNS Drugs|March 17, 2015
Fertility, pregnancy and childbirth in patients with multiple sclerosis: impact of disease-modifying drugsMaria Pia Amato, Emilio Portaccio
CNS Drugs|June 2, 2009
Improving compliance with interferon-beta therapy in patients with multiple sclerosisEmilio Portaccio, Maria Pia Amato
Pageof 16